Overview

Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder: Proof of Concept

Status:
Not yet recruiting
Trial end date:
2022-09-15
Target enrollment:
Participant gender:
Summary
This is a proof-of-concept, open-label trial of pimavanserin 34mg at bedtime for 6 weeks in Veterans with insomnia and Posttraumatic Stress Disorder.
Phase:
Phase 4
Details
Lead Sponsor:
Baylor College of Medicine
Collaborator:
ACADIA Pharmaceuticals Inc.
Treatments:
Pimavanserin